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This chapter is dedicated to the loving memory of Prof. Ricardo Renzo Brentani,  
a brilliant scientist, a source of inspiration for younger generations and a wonderful man. 
1. Introduction 
1.1 Neurodegenerative disorders and transmissible spongiform encephalopathies 
Neuronal death represents the primary pathology of neurodegenerative diseases such as 
Alzheimer's and Parkinson’s disease and Amyotrophic Lateral Sclerosis. These diseases 
usually present with a slow onset and a chronic progression. Various regions of the brain, 
spinal cord, or peripheral nerves may be affected, leading to functional impairment and 
neuron loss. Neurodegenerative diseases are often categorized by symptoms that may 
include impairment in cognition, movement, strength, coordination, sensation, or 
autonomic control. However, the diagnosis of a specific neurodegenerative disease may be 
misleading, as there is both clinical and neuropathologic overlap among diseases and 
existing diagnostic tools are not always accurate. For most neurodegenerative diseases, 
neuronal dysfunction, such as synaptic loss, may occur long before neuronal death takes 
place (Soto, 2003;Shastry, 2003;Aguzzi and O'Connor, 2010).  
A group of neurodegenerative diseases called protein conformational disorders includes 
relatively common diseases as well as some rare inherited disorders that involve the 
deposition of protein aggregates in the brain, leading to the selective loss of neurons in an 
age-dependent manner. The protein conformational disorders include Alzheimer’s disease 
(AD), Parkinson’s disease (PD), Huntington’s disease (HD), as well as polyglutamine 
disorders that include several forms of spinocerebellar ataxia, amyotrophic lateral sclerosis, 
and the transmissible spongiform encephalopathies (TSEs), also referred to as prion diseases 
(Table 1). These disorders affect a diverse neuronal population in discrete regions of the 
brain. Until recently, there were no molecular mechanisms known to be shared by all these 
diseases. However, accumulating evidence implicates protein misfolding and aggregation as 
a likely common underlying cause (Soto, 2003;Shastry, 2003;Aguzzi and O'Connor, 2010).  
Correct cell maintenance depends upon the activity of proteins, whose function relies upon 
their three-dimensional structure. However, some proteins can also fold into stable 
alternative conformations that result in their aggregation and accumulation as fibrillar 
deposits. Although these deposits have similar morphological, structural, and 
staining/immunoreactivity characteristics, protein deposits found on different diseases may 
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also have distinct biochemical or biological features. The precise causes of abnormal folding 
and accumulation of proteins are not understood. There is currently considerable debate 
regarding the toxic versus neuroprotective effect of aggregates, and whether small soluble 
oligomers of the same proteins, may represent the toxic entities (Aguzzi and O'Connor, 
2010;Shastry, 2003;Soto, 2003). 
The rarest, yet the most intriguing, of these protein conformational disorders are the TSEs or 
prion diseases. This group of diseases includes Creutzfeldt–Jakob disease (CJD), kuru, fatal 
familial insomnia (FFI), and Gerstmann–Straussler–Scheinker syndrome (GSS) in humans, 
scrapie in sheep, bovine spongiform encephalopathy (BSE) in cattle, and chronic wasting 
disease in cervids (Soto, 2003;Shastry, 2003;Aguzzi and O'Connor, 2010;Aguzzi et al., 
2001;Aguzzi and Polymenidou, 2004;Gibbs, Jr. et al., 1968;Masters et al., 1981;Medori et al., 
1992a;Medori et al., 1992b). 
 
Diseases Clinical Features Structures affected Likely cause 
Alzheimer’s disease Progressive dementia 
Hippocampus, 
cerebral cortex 
Amyloid deposits 
Amyotrophic lateral 
sclerosis  
Movement disorder 
Motor cortex, 
brainstem 
Superoxide dismutase/ 
TDP-43 deposits 
Charcot Marie Tooth Muscular weakness PNS 
Axonal degeneration / 
demyelinization 
Corticobasal 
degeneration 
Impairment on 
cognition and 
movement 
cerebral cortex and 
the basal ganglia 
Unknown 
Dementia with Lewy 
bodies 
Impairment on 
cognition and 
movement 
Cerebral cortex 
Lewy bodies – deposits 
of synuclein and 
ubiquitin 
Friedreich’s ataxia 
Coordination 
problems 
Spinal cord and 
peripheral nerves 
Mutation in Frataxin 
gene 
Huntington’s disease 
Dementia, motor and 
psychiatric problems 
Striatum, cerebral 
cortex 
Huntingtin deposits 
Multiple Sclerosis 
sensory disturbance, 
visual loss, motor 
dysfunction  
spinal cord and optic 
nerves 
Demyelination 
Parkinson’s disease Movement disorder 
Substantia nigra, 
hypothalamus 
Synuclein deposits 
Pick’s disease 
behavior changes, 
speech difficulty, and 
impaired thinking 
frontal lobes 
Pick bodies, 
accumulation of Tau 
Prion disorders 
Dementia, ataxia,  
or psychiatric or 
insomnia problems  
Various regions 
depending on the 
disease 
Prion protein deposits 
Progressive 
supranuclear palsy 
Impairment on 
cognition and 
movement 
most areas of the 
brain and in some 
parts of the spinal 
cord 
unknown 
Polyglutamine 
Diseases / 
Spinocerebellar ataxia 
Coordination 
Problems 
Cerebellum/ spinal 
cord 
Accumulation of 
proteins (ataxins) 
presenting poly-Q 
repeats 
Table 1. Brief list of well characterized neurodegenerative diseases (not inclusive, and 
diseases can present in ways in which they have not been listed). Protein conformational 
disorders are highlighted in bold. PNS = peripheral nervous system.  
www.intechopen.com
 Transmissible Spongiform Encephalopathies 
 
189 
The most unique feature of the prion diseases is that they present both hereditary and 
transmissible forms and, as we will present further in this chapter, the identification of 
proteins as transmissible disease agents represents a breakthrough in the concepts of 
modern biology. Prion diseases are generally characterized by the aggregation of prions, 
also referred to PrPSc, into large plaques that are associated with the rapid loss of neurons in 
specific areas of the brain and corresponds to the onset of neurological and behavioral 
symptoms. The PrPSc protein is the abnormal isoform of the cellular prion protein (PrPC) 
that is normally present in all tissues of the body and whose expression is particularly high 
in neurons. A change in the three-dimensional structure of PrPC renders it into the highly 
insoluble PrPSc, which is resistant to degradation and proteinase digestion. The presence of 
PrPSc can alter the conformation of PrPC in the cell, thus making it a productive infection. 
The unusual properties of prion propagation have presented challenges to researchers 
seeking to understand the pathogenic mechanisms of these diseases and have slowed the 
development of effective diagnostic tools and therapeutic strategies (Soto, 2003;Shastry, 
2003;Aguzzi and O'Connor, 2010). 
This chapter will focus on human prion disorders, their history, etiology, symptoms, and the 
therapeutic strategies tried so far. Instead of a comprehensive review of the abundant prion 
literature, our goal here is to present a general view of the mechanism of these diseases for 
the lay public, complemented by a list of references that will enable additional study for 
those who wish to further explore the mysteries of prions.  
2. A historic overview 
This section will present a historic view of the TSEs, from the early descriptions of scrapie, 
the prototypic prion disease that affects sheep and goats and which has been a concern since 
the 18th century, to kuru, an endemic form of human TSE that was transmitted via 
cannibalistic rituals among the aborigines of Papua New Guinea throughout the 1950s and 
1960s. We will also discuss the transmission of prions via contaminated meat that resulted in 
patients who contracted a new variant of Creutzfeldt-Jakob disease and led to one of the 
largest catastrophes in the history of medicine. 
2.1 From scrapie to kuru – The discovery of infectious prions 
The disease named scrapie affects sheep and has been a matter of concern since the 18th 
century, mystifying farmers and negatively impacting local economies (Aguzzi, 2006). The 
name “scrapie” originates from the behavior of compulsive rubbing and scraping against 
fixed objects observed in affected sheep. Scrapie could be found in many countries of 
Europe, such as France, in which is called tremblante (trembling), Spain (Basqvilla disease), 
Germany (traberkrankheit – trotting disease), and Iceland (rida – tremor) amongst others, in 
addition to regions in Asia such as India and the Himalayas (Khujali or Mokoo) (Schneider 
et al., 2008;Prusiner, 1999).  
Early descriptions of scrapie date back to the 17th century (Adams, 1975) or earlier, 
possibly including explicit references by agricultural writers at the time of the Romans 
(Schneider et al., 2008). The symptoms of scrapie are characterized by progressive ataxia, 
particularly in the hind limbs, and collapse. The disease typically affects sheep around 
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four years of age and progresses rapidly, within weeks to months, to death of the animal 
(Adams, 1975). Naturally infected sheep may have an asymptomatic incubation period 
that varies from three to five years, during which there is no febrile phase or alterations in 
cerebrospinal fluid composition. The lesions of scrapie are limited to the central nervous 
system (CNS) and are concentrated in the cerebellum, where widespread neuronal 
degeneration and the prominent hypertrophy and proliferation of astrocytes are typical 
features (Adams, 1975). 
Different theories have emerged during the 20th century regarding the nature of the 
etiological agent of scrapie, and a “slow-virus” hypothesis was predominant until the 
revolutionary “protein-only” proposal that suggested that scrapie could spread in the 
absence of DNA (Schneider et al., 2008;Prusiner, 1999;Griffith, 1967). Experiments in sheep 
demonstrating a lengthy incubation period enabled the proposal of the “slow-virus” 
hypothesis. The unknown agent presented some viral features, such as the ability to spread 
and cause disease in other sheep indefinitely. In addition, the infectious agent could be 
filtered and appeared to be self-replicating. Moreover, this agent had been detected in most 
tissues including brain, spinal cord, pituitary gland, adrenal gland, salivary glands, spleen, 
liver, and lymphatic glands (Schneider et al., 2008).  
However, the initial experimental studies did not show evidence of the agent being 
present and active in tissue culture models or detectable via serology or electron 
microscopy (Adams, 1975). In these studies, the scrapie agent puzzled investigators with 
properties that challenged the current knowledge regarding viruses, such as its 
remarkable resistance to a number of physical and chemical treatments that destroy 
conventional viruses.  
The possibility that the scrapie agent did not contain nucleic acids suggested that a hitherto 
unrecognized agent could be involved in this disease (Adams, 1975). In agreement with 
these findings, early evidence of an unconventional transmission of scrapie arose 
accidentally in 1930’s in Scotland. In an attempt to vaccinate sheep against infectious 
encephalomyelitis caused by a virus (looping-ill virus), the animals received inoculums 
derived from the brain and spleen of affected animals that had been treated with formalin. 
The tissues used to produce the “inactivated virus” were, in fact, contaminated with scrapie, 
which caused the disease in a fraction of the animals that received the inoculum, suggesting 
that the agent involved in this disease was resistant to formalin treatment (Prusiner, 
1999;Gordon, 1946).  
Following the findings of experimental transmission of scrapie in sheep, little progress in 
the field was made until Carleton Gajdusek demonstrated that kuru, a human disease 
responsible for a high mortality in the Fore people from Papua, New Guinea, was a 
transmissible spongiform encephalopathy.  
This story begins in 1955, after an invitation made by Vincent Zigas, a physician of the 
Fore region, to his colleague Carleton Gajdusek, who had a strong background in 
microbiology, to help understanding the increasing incidence of a strange disease the 
aborigines called kuru. At that time, approximately 10% of the Fore people were dying of 
kuru each year, and women and children were particularly affected (Zetterstrom, 2010) 
(Figure 1).  
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Fig. 1. Dr Carleton Gajdusek (left) and Dr Vincent Zigas study a child patient with kuru at 
Okapa in 1957. Reproduced with permission from Gajdusek in: Phil. Trans. R. Soc. B (2008) 
363, 3636–3643 (Gajdusek, 2008). 
Gajdusek and Zigas first described the clinical symptoms of kuru (the name means 
shivering or trembling in the Fore language) in 1957 (Zetterstrom, 2010). They described the 
disease as subacute and characterized by progressive cerebellar ataxia manifesting as 
athetoid movements that progresses to complete motor incapacity and, although cognition 
was generally unaffected, kuru was invariably fatal, patients typically died within 3–9 
months after disease onset (Gajdusek and Zigas, 1957). However, the clinical and 
epidemiological profiles suggested that this was indeed a peculiar disease, as brains 
autopsies showed spongiform encephalopathy, suggesting that, like scrapie, kuru was an 
infectious disease (Gajdusek and Zigas, 1959; Zetterstrom, 2010; Harper, 1977).  
A genetic explanation was initially proposed based in the apparent restriction of the disease 
to a particular tribal group and the remarkable familial clustering, with vertical transmission 
from generation to another (Harper, 1977). The elucidation of the causative factors of kuru 
came from the elegant experimental approaches and epidemiological studies carried out by 
Gajdusek and others (Harper, 1977;Zetterstrom, 2010). They demonstrated that ritual 
cannibalism of the brain and other parts of deceased relatives, practiced by the family, 
particularly by women and children, as an act of mourning and respect, provided the clue to 
the discovery that consumption of kuru-contaminated tissue was the means of transmitting 
the disease (Gajdusek, 1977). These findings led to the successful transmission of the disease 
to chimpanzees by the intracerebral inoculation of brain tissue from kuru patients (Harper, 
1977;Gajdusek et al., 1966). 
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As in scrapie, the infectious agent of kuru accumulated in great quantities in the brain and 
did not have the features of a typical viral pathogen. These observations led Gajdusek to 
speculate that an unconventional type of virus might be the etiological agent of kuru, and 
this view was supported by the experimental transmission of kuru, scrapie and also 
Creutzfeldt–Jakob disease to chimpanzees during the 1960s and 1970s (Gajdusek et al., 
1966). 
These findings led to a new vision of the etiology of various neurodegenerative diseases, 
which garnered Gajdusek the Nobel Prize in 1976 (Zetterstrom, 2010). However, the 
“protein only” hypothesis came from the mind of J. S. Griffith, a mathematician (Griffith, 
1967). He presented different models of transmission solely by protein particles with the 
ability to modify native proteins. The term “prion” was introduced in 1982 by Stanley 
Prusiner to describe an infectious proteinaceous particle (Prusiner, 1982).  
The elucidation of the true chemical nature of prions occurred in the 1980s, following the 
isolation of infectious material from affected brains of Syrian hamsters (Bolton et al., 
1982). This material was highly insoluble, with characteristics typical of amyloid 
aggregates (Prusiner et al., 1983), and was resistant to treatments that inactivate nucleic 
acid activity. Conversely, the infectious ability of prions was completely abrogated by 
moieties that modify protein activity and structure, such as proteases and detergents, 
strengthening the concept of the prion being an infectious “protein-only” agent. The 
isolation of prions permitted the characterization of a native protein synthesized by the 
host genome, termed the cellular prion protein (Oesch et al., 1985;Meyer et al., 1986). To 
characterize the infectious agent of transmissible spongiform encephalopathies, the prion 
protein gene was cloned from host cells by Dr. Prusiner, who went on to discover that 
changes in the three-dimensional structure of the native prion protein was the cause of 
these disorders. For this work, Dr. Prusiner was awarded the Nobel Prize in 1998 
(Schneider et al., 2008).  
The importance of these findings extended far beyond simply elucidating the means of 
transmission of a disease; they have broken a biology dogma that stated that information 
passing from one organism to another must be mediated by nucleic acids. From the 
discovery of prions, scientists knew that proteins were also able to transmit information 
from one organism to another. 
2.2 The BSE epidemic and transmission to humans 
Coincident with the period in which the elucidation prion biology was the focus of TSE 
studies came the “mad-cow disease.” In the mid-1980s, an epidemic of bovine spongiform 
encephalopathy (BSE; commonly known as mad-cow disease) had a major impact on the 
human health policies as well as the economies of Europe, particularly the United 
Kingdom (UK), and Canada (Tyrrell and Taylor, 1996;Prusiner, 1999). In the UK, the 
incidence of BSE in cattle peaked at 370,000 cases in 1992, and has steadily diminished 
since (Zetterstrom, 2010). The incubation period of BSE varies from 2 to 8 years and thus 
affects adult cattle. Importantly, all breeds of cattle are equally susceptible to the infection 
(Chesebro, 2003).  
Several pieces of evidence suggested that BSE was transmitted from sheep to cows via 
contaminated feed in the 1980’s (Stack et al., 2006;Wells and Wilesmith, 1995). The epidemic 
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began simultaneously at many geographic locations in England and was traced to the 
contamination of meat and bone meal derived from scrapie-infected sheep that was used in 
cattle feed. The spread of BSE was likely accelerated by the recycling of infected bovine 
tissues to manufacture feed, a practice halted following the recognition of BSE (Nathanson 
et al., 1997). The onset of the BSE epidemic was coincident with modifications in the process 
of extracting fat from meat and bone meal that unknowingly allowed prion particles to 
remain active (Wilesmith et al., 1991).  
The BSE epidemic provoked much alarm in societies worldwide, as it had been associated 
with a new human disease, known as variant CJD (vCJD), that had been observed in 
individuals who had eaten infected cattle meat (Aguzzi, 2006;Aguzzi and Weissmann, 
1996;Hill et al., 1997a). Despite concerns about a potential epidemic of vCJD, the total 
number of victims was relatively small (Valleron et al., 2001;Aguzzi, 2006). However, the 
risk of acquiring CJD is not limited to consumption of BSE-contaminated meat, as the 
transmission of prions has also been documented to occur during clinical procedures 
(iatrogenic transmission) (Aguzzi, 2006;Brown et al., 1992). Cases of CJD have been 
attributed to the transplantation of tissues or from pituitary hormone derived from deceased 
individuals that had unrecognized or asymptomatic TSE at the time of death. The 
contamination of medical instruments during neurosurgical interventions was also of 
concern, as patients with CJD were documented to have undergone invasive procedures, 
including brain biopsies (Will et al., 1999). Moreover, transmission of CJD was observed in 
patients submitted to depth electroencephalogram (EEG) recordings using electrodes that 
had previously been used in a CJD patient (Bernoulli et al., 1977). Evidence was also 
presented for prion transmission via human blood and derivatives; however, controversy 
still exists regarding the presence of CJD infectivity in human blood (Brown, 1995;Will et al., 
1999). 
3. Human forms of TSE  
In humans, TSE has been classified into three subtypes: infectious (kuru, iatrogenic (i) CJD 
and variant (v) CJD), in which transmission has occurred because of human intervention, 
heritable familial (fCJD, GSS, and FFI) forms, and sporadic (sCJD) in which the disease 
cannot be linked to any of the previous forms of infection. In all three subgroups, the TSE 
can be transmitted to primates via ingestion or inoculation (Brown et al., 1994), thus 
fulfilling one of the main characteristics of TSE diseases, transmissibility. 
Kuru was the first human neurodegenerative disease to be transmitted to laboratory 
primates (Gajdusek et al., 1966) and classified as a TSE. The most striking sign of the 
disease is a fine tremor of the head, trunk, and limbs that is associated with the insidious 
onset of ataxia. Both the ataxia and tremor become more pronounced as the disease 
progresses, and these signs are joined by other indicators of cerebellar pathology, as well 
as behavioral abnormalities (Gajdusek and Reid, 1961). Following the cessation of ritual 
cannibalism in the Fore people of Papua New Guinea, the incidence of kuru has steadily 
decreased to its current low levels (Collinge et al., 2006). The incubation period of this 
disease can be as long as 56 years, according to reports. Analysis of the PrPC gene showed 
that most kuru patients were heterozygous for a polymorphism at codon 129 (presenting 
both a methionine and a valine at this position - M129V), a genotype associated with 
extended incubation periods and resistance to prion disease (Collinge et al., 2006). 
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Pathologically, kuru is characterized by a mild to moderate degree of neuronal 
vacuolation, an intense astrocytic gliosis, cerebellar degeneration, and the presence of 
numerous amyloid plaques that tend to be most common in the cerebellum, but can also 
be widely distributed in the brain. 
CJD is the most common human TSE (the name Creutzfeldt-Jakob disease was coined by 
Spielmeyer in 1922), which has been shown to have familial (fCJD), infectious 
(iatrogenic/iCJD and variant/vCJD), and sporadic (sCJD) etiologies. Approximately 85% of 
all human prion diseases are sporadic forms of CJD, with incidences of 0.6-1.2 cases per 
million people per year distributed equally between men and women (Ladogana et al., 
2005). The cause of sCJD is still unclear, although the spontaneous misfolding of PrPC to 
PrPSc is a plausible hypothesis (Prusiner, 1989;Hsiao et al., 1991a). Alternate explanations 
include somatic mutations in the PrPC gene that could lead to abnormal protein folding, 
even though no case of somatic mutations has been reported. However, the M129V 
polymorphism in the PrPC gene appears to be associated with a lower risk (Palmer et al., 
1991) and/or prolonged incubation time (Collinge et al., 2006). It remains possible that sCJD 
could be an acquired illness, as two case-control studies have reported prior surgery as a 
risk factor (Ward et al., 2002;Collins et al., 1999). However, evidence that these factors 
directly contribute to the etiology of sCJD is still lacking. 
Unlike other diseases with dementia, such as Alzheimer’s and Parkinson’s diseases, in 
which incidence rises with age, the incidence of sCJD is primarily between 55 and 60 years 
of age, although patients as young as 14 (Murray et al., 2008) and as old as 86 (de et al., 
1997) years of age have been reported. sCJD is a rapidly progressing dementia, and 
usually leads to death within a few weeks of the first symptoms. Initial symptoms include 
very rapid cognitive decline and dementia, sleep disturbances, and behavioral 
abnormalities consistent with proeminent cerebral atrophy (Figure 2). Cerebellar 
symptoms including ataxia and myoclonus are often present. Visual disturbances and 
ocular movement disorders, as well as extrapyramidal signs and hallucinations may also 
occur with sCJD. The final stages are characterized by an akinetic mute state (Murray, 
2011). The rapidity of deterioration in sCJD usually allows the clinician to distinguish it 
from other dementias and neurodegenerative conditions. Pathological findings consist 
primarily of astrocytosis and spongiform changes associated with loss of neurons. The 
abnormal protease-resistant PrPSc can frequently be detected directly by 
immunohistochemistry in properly treated brain sections. Amyloid plaques containing 
PrPSc are also present in 5% of cases (Brown et al., 1994). 
While variant CJD (vCJD) is associated with the consumption of BSE-infected meat, 
another CJD acquired by infection is iatrogenic CJD (iCJD), which is believed to result 
from the patient’s exposure to prions by contact with contaminated human tissues. iCJD 
can be inadvertently transmitted during the course of medical or surgical procedures, 
either by the transplantation of tissues from patients with TSE or by neurosurgery using 
instruments incompletely sterilized following use on TSE patient (Aguzzi and 
Polymenidou, 2004). The first reported case of iCJD occurred in 1974 and was caused by 
the corneal transplantation of a graft derived from a patient suffering from sCJD (Duffy et 
al., 1974). Iatrogenic CJD is rare and is most often observed in individuals that have 
received cadaveric dura mater implants, human growth hormone, or were placed 
contaminated brain electrodes (Will, 2003).  
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Fig. 2. Macroscopical aspect of a sporadic CJD brain with prominent cerebral, but not 
cerebellar, atrophy. Reproduced with permission from Budka, British Medical Bulletin 2003; 
66: 121–130 (Budka, 2003). 
The incubation period for iCJD is long, ranging from two to more than ten years. Additional 
evidence indicates that the route of prion exposure influences the clinical manifestation of CJD. 
For example, a predominantly ataxic phenotype is observed for dura mater or growth 
hormone-related cases, whereas cases in which prions were directly introduced into the CNS 
present with dementia as the initial symptom (Glatzel et al., 2005).  
The newest version of human TSE, vCJD, was first reported in 1996 (Will et al., 1996) and 
was linked to the consumption of food contaminated with the BSE agent. In recent years, 
several studies regarding the biochemical, neuropathologic, and transmission 
characteristics of vCJD confirms that this disease represents the transmission of BSE 
prions to humans (Aguzzi, 1996;Aguzzi and Weissmann, 1996;Bruce et al., 1997;Hill et al., 
1997a). In contrast to traditional forms of CJD, vCJD has affected younger patients 
(average age 19-39 years, as opposed to 65 years), has a relatively long duration of illness 
(median of 14 months as opposed to 4.5 months), and is strongly linked to exposure, 
probably through consumption, to cattle BSE (Will et al., 2000). The young age range of 
these patients and their distinctive pathology indicated that they represented a novel 
clinical TSE disease, combined with the initial occurrence of these patients in the UK, 
suggested an association with bovine BSE (Will et al., 1996). Subsequent laboratory 
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experiments suggested that a strong similarity existed between BSE and vCJD on the basis 
of the lesion distribution in these disorders. Approximately 200 people have been 
diagnosed with vCJD world-wide, with most affected individuals being from the UK and 
France. Since 2001, the incidence vCJD in the UK appears to have stabilized 
(http://www.cjd.ed.ac.uk). The predominant clinical presentation for vCJD involves 
psychiatric symptoms, including behavioral changes, anxiety, and depression. These 
symptoms are followed, within weeks to months, by a cerebellar syndrome with ataxia 
and subsequent myoclonus. Later in the course of the disease, memory disturbances are 
evident, which progress to severe cognitive impairment and, finally, akinetic mutism. 
Neuropathological analyses have shown spongiform changes, neuronal loss, and 
astrogliosis, most prominently in the basal ganglia and thalamus. In addition, striking 
amyloid plaques containing PrPSc may be present throughout the cerebrum and 
cerebellum, and are often surrounded by vacuoles (Will et al., 1996). 
The familial/inherited human prion diseases can be subdivided into three phenotypes, 
including fCJD, GSS, and FFI, according to the clinical symptoms presented. Familial 
prion diseases are far more rare than sCJD, and account for 10 to 20% of all TSE cases with 
an incidence of approximately 1 per 10 million. Familial TSEs are associated with an 
autosomal dominant alteration in the gene that encodes the PrPC protein (Hsiao et al., 
1989). To date, over 40 different mutations in this gene have been described to segregate 
with TSEs (Table 2).  
 
Diseases Mutations 
GSS P102L-129M 
P105L-129V 
A117V-129V 
G131V-129M 
Y145*-129M 
H187R-129V 
F189S-129V 
D202N-129V 
Q212P 
Q217R-129M 
fCJD  D178N-129V 
V180I 
T188K 
T188R-129V 
E196K 
E200K  
V203I 
E208H 
V210I 
E211Q 
M232R 
FFI D178N-129M 
Table 2. Summarizes known mutations that cause human TSEs. Point mutations found in 
patients with prion disease in the gene that codes for PrPC. In some cases, the mutations are 
found in association with a polymorphism in codon 129, where methionine (M) or valine (V) 
are indicated. Amino acids are given in single-letter code. The asterisk indicates a stop 
codon; consequently, this mutation results in a truncated protein. 
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Several different mutations in the gene encoding PrPC have been implicated in fCJD 
(Goldfarb et al., 1990;Hsiao et al., 1991b;Hsiao et al., 1991a;Bertoni et al., 1992). The 
clinicopathological phenotype of fCJD varies depending upon the mutation, as well as on the 
presence of a polymorphism at amino acid 129 (methionine (M) or valine(V)) (Kovacs et al., 
2002). Highly variable symptoms may present even in affected members of the same family. 
The pattern of symptoms is sometimes similar to that observed for sCJD. Early symptoms 
may include depression, memory lapses, social withdrawal, and a lack of interest. However, 
the rapid progression to dementia and neurological symptoms are diagnostic. Within weeks, 
the patient may become unsteady on their feet, lack coordination, experience blurred vision 
or even blindness, rigidity in the limbs, and difficulty in speaking. In fCJD, the average age of 
onset symptoms is 52 years of age, compared to 65 years for sCJD. 
A mutation in the gene encoding for PrPC that results in an aspartate (D) to asparagine (N) 
substitution at amino acid 178 (D178N) can underlie either fCJD or FFI, depending on the 
polymorphism present at amino acid 129 (M or V). D178N coupled with V129 produces 
fCJD, in which patients present dementia and a widespread deposition of prion protein in 
the brain (Goldfarb et al., 1991a;Goldfarb et al., 1991b). When D178N is coupled with M129, 
the result is FFI.  
The FFI diagnosis was first used in 1986 to describe an illness affecting five members of a 
large Italian family (Lugaresi et al., 1986). Over 20 kindred and seven nonfamilial (sporadic) 
cases of this unusual variety of prion disease have since been identified throughout the 
world. In the most characteristic presentation, the patient with FFI develops untreatable 
insomnia, sometimes for a prolonged period of weeks or months. Insomnia is followed by 
dysautonomia, ataxia, and variable pyramidal and extrapyramidal signs and symptoms, 
with a relative sparing of cognitive function until late in the disease course. The 
dysautonomias may include episodic alterations in blood pressure, heart rate, temperature, 
respiratory rate, and secretions. Electroencephalogram (EEG) recordings performed on these 
patients shows diffuse slowing, rather than periodic, discharges. Positron emission 
tomography (PET) reveals a reduction in metabolic activity in, or blood flow to, the 
thalamus relatively early in the disease (Padovani et al., 1998). The average age of onset for 
FFI is 50 years of age, with an average disease duration of 12 months. 
The neuropathologic features of FFI include neuronal loss and astrogliosis within  
the thalamus and inferior olives and, to a lesser degree, the cerebellum. Vacuolation  
is minimal or absent in typical cases. Protease-resistant PrPSc is detectable in the brains  
of affected patients; however, it is usually present only in small amounts and is  
often restricted to specific regions such as the thalamus and temporal lobe 
(http://www.medscape.com/viewarticle/410863_4). 
A specific mutation in the gene encoding PrPC, which results in a proline (P) to leucine (L) 
substitution at amino acid 102 (P102L), was found to be present in patients with GSS. This 
was first detected in the original Austrian family described by Gerstmann, and was later 
observed in other cases (Hainfellner et al., 1996). This finding led to the unprecedented 
conclusion that prion diseases can have both genetic and infectious etiologies (Hsiao et al., 
1989;Prusiner, 1989). This mutation has been found in unrelated families from several 
countries (Goldgaber et al., 1989;Kretzschmar et al., 1991) and other mutations causing GSS 
have also been identified. GSS is characterized by a slowly progressive cerebellar ataxia 
accompanied by cognitive decline (Ghetti et al., 1995). In contrast to other inherited human 
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prion diseases, GSS has unique neuropathologic features that consist of widespread, 
multicentric PrPSc plaques in the cerebellar cortex. In families with GSS, symptoms usually 
begin in the fifth or sixth decade of life, but disease onset may occur as young as 25 years of 
age, with illness durations ranging from three months to 13 years (mean five to six years) 
(Chabry et al., 1999;Masters et al., 1981;Gajdusek, 1977;Hill et al., 1997a). Variation in the age 
of onset is associated with the presence of the P102L mutation (Deslys et al., 1996). 
4. Transmission of prions 
The most notorious means of prion transmission is via the ingestion of contaminated meat, 
although transmission by this route is actually highly inefficient. The concept of prion 
infectivity was presented to the general population during the rise of the mad-cow disease 
epidemic and the recognition of vCJD. vCJD was reported for the first time in 1996 as a 
disease having a clinical and pathological phenotype distinct from sCJD. Following many 
years of investigation, it became clear that vCJD is caused by consumption of BSE-
contaminated meat products. Since 1996, 223 cases of vCJD have been reported, most 
occurring in the UK and France, although other countries have also reported cases (Table 3) 
(Ironside, 2010). The most likely period for transmission of BSE to humans was from 1984-89 
and 1995-96 during the outbreak of BSE in cattle. Although a major portion of the UK 
population was likely exposed to BSE infectivity, a relatively small number of individuals 
have died from vCJD (Knight, 2010). Reasons for this low incidence may include a 
significant inter-species barrier, inefficiency of oral ingestion as a route of transmission, as 
well as difference in individual susceptibility.  
Iatrogenic transmission of CJD is relatively rare. To date, iCJD has been reported in more than 
400 patients who were exposed to prion transmission via contaminated neurosurgical 
instruments, intracerebral electroencephalographic electrodes, human pituitary hormone, 
corneal transplant, or dura mater graft. iCJD was first suggested in the case of a woman who 
died of CJD in 1974. She had received a corneal transplant 18 months before disease onset, 
derived from a patient who also died of CJD (Duffy et al., 1974). In 1997, a 45-year-old German 
woman developed CJD 30 years after corneal graft from a donor with confirmed CJD. Another 
eight cases of suspected contamination through corneal transplant have been reported, but the 
status of the donor in these cases has not been confirmed (Hamaguchi et al., 2009).  
 
Country 
Number of cases 
(October 2011) 
United Kingdom 176 
France 25 
Spain 5 
Ireland 4 
Netherlands 3 
United States of America 3 
Portugal 2 
Italy 2 
Canada 1 
Saudi Arabia 1 
Japan 1 
Table 3. Variant CJD cases worldwide.  
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The first case of dura mater graft-associated CJD (dCJD) was reported in the US in 
1987(1987). Since then, 196 dCJD cases have been described, more than 50% of which 
occurred in Japan (Hamaguchi et al., 2009). 
Another iatrogenic means of prion transmission resulted from the treatment of children 
with short stature with human growth hormone (hGH) that was derived from pituitary 
glands from the corpses of CJD-affected individuals. The process of purifying hGH did not 
eliminate prion infectivity causing this kind of contamination. To date, more than 190 
patients worldwide have presented with iCJD following hGH treatment. More than 100 
cases occurred in France (Hamaguchi et al., 2009), and others have been described in the UK, 
US, New Zealand, Brazil, and others (Brown et al., 2006). Although the use of recombinant 
GH began in 1985, cases of hGH-associated iCJD are still being observed due to the 
prolonged incubation period, up to 20 years, observed for these iCJD cases.  
Thus, the length of the incubation period for the CJDs appears to be related to the means by 
which the prion particles were transmitted. Direct intracerebral exposure to prions via 
contaminated surgical material and the implantation of prion-contaminated dura mater, for 
example, have been associated with relatively short incubation periods (16-28 months). 
Peripheral exposure to prions, through the consumption of contaminated meat or exposure 
to contaminated hGH, results in longer incubation times that range from 5 to 30 years 
(Glatzel et al., 2005). 
The occurrence of secondary transmission of CJD via blood transfusion has been reported. 
This route of human to human iCJD transmission has particularly important implications 
for public health, as relatively high infectivity has been observed in the lymphoid tissues of 
CJD patients. The existence of subclinical infected donors, combined with the high CJD 
infectivity of blood and the efficiency of blood as a route of transmissions, are key factors 
influencing the likelihood of acquiring iCJD via transfusion. To date, there are four 
confirmed cases of iCJD associated with the transfusion of non-leukoreduced red blood cells 
from an asymptomatic donor who subsequently died from vCJD (McCutcheon et al., 2011). 
The incubation time in the recipients was approximately 7 years after the contaminated 
transfusions (Ironside, 2010). 
5. Diagnosis  
Although a rapidly progressive dementia, myoclonus, and other neurological signs may 
lead the clinician to suspect a TSE, the definitive diagnostics in humans can only be 
confirmed by brain biopsy or necropsy followed by the histopathological and 
immunohistochemical examination of brain tissue. Cerebral biopsy in living patients is 
discouraged, unless its purpose is to achieve an alternative diagnosis of a treatable disorder.  
The misfolded prion protein, PrPSc, is the single most significant marker for the TSE 
diseases, but its detection using standard serological methods is complicated by its antigenic 
similarity to the normal prion protein, PrPC. Many research groups have tried to detect PrPSc 
outside of the brain in order to develop more accurate and less invasive diagnostic tools, but 
these attempts have so far been unsuccessful or are still in clinical trials. Electrophysiological 
examinations using EEG, or imaging exams using magnetic resonance imaging (MRI), 
combined with biochemical analysis, are among the methods currently used to probe for 
prion diseases, as discussed below (Venneti, 2010). In the following section we will present 
the main features of the diagnostic tools that have, to date, been in use. 
www.intechopen.com
 Brain Damage – Bridging Between Basic Research and Clinics 
 
200 
5.1 Genetic investigations 
DNA sequencing of the gene that encodes PrPC can detect the inherited forms of prion 
diseases that are caused by point mutations. There have been 55 pathogenic mutations 
described in the gene that encodes PrPC (Table 2) which include 24 missense point mutations, 
27 insertion mutations, 2 deletions, and 2 nonsense mutation that result in the premature 
termination of the PrPC protein. If DNA sequencing detects a mutation in a patient, the 
diagnosis of TSE can be confirmed (Figure 3). However, the absence of detectable mutations 
does not exclude the sporadic or iatrogenic forms of the disease (Gambetti et al., 1999).  
Twelve polymorphisms that do not result in amino acid substitution have been described in 
the gene encoding for PrPC (Gambetti et al., 1999). Four additional polymorphisms that do 
alter the amino acid sequence of PrPC have also been reported. The polymorphism at amino 
acid 129 of PrPC is of particular importance; compelling evidence from studies in genetically 
modified mice as well as from clinical studies indicate that homozygosity for the less 
common methionine at position 129 constitutes a risk factor for the development of prion 
disease. Notably, methionine homozygotes are overrepresented among patients with sCJD, 
and all individuals affected by vCJD are codon 129 methionine homozygotes. Besides 
constituting a risk factor for the development of prion diseases, this polymorphism has a 
considerable effect on the clinical, biochemical, and neuropathologic presentation of 
individuals with prion diseases (Glatzel et al., 2005). As described in previous sections, a 
mutation in PrPC at amino acid 178, when combined with the presence of methionine at 
position 129, results in the development of CJD or FFI. 
 
Fig. 3. Genomic sequencing of PrPC encoding gene. This particular test shows a mutation 
(AAG to GAG) in heterozygosis that would code for amino acid 200, replacing a glutamate 
for a lysine (E200K).  
5.2 EEG  
EEG recording show periodic or pseudoperiodic paroxysms of triphasic or sharp waves of 
0.5 to 2.0 Hz against a slow background in about two-thirds of sCJD patients. However, this 
EEG pattern is not specific to sCJD, and occurs in other conditions, such as metabolic 
diseases. In addition, at least 30% of cases may not demonstrate the typical features. There 
appears to be a temporal window of opportunity for the detection of abnormal EEG patterns 
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in sCJD, as these patterns may not be evident either early or late in the disease course. Thus, 
a serial course of weekly or bi-weekly EEGs may be necessary to capture the characteristic 
periodic discharges (Will et al., 1999).  
In iCJD, the EEG shows a slow wave pattern and, in FFI, the EEG displays diffuse slowing, 
rather than rather than the periodic triphasic discharges typical of sCJD (Will et al., 1999). 
5.3 MRI 
Although the use of MRI is not included in the exams recommended by the World Health 
Organization (WHO) (http://www.who.int/entity/zoonoses/diseases/Creutzfeldt.pdf), it 
can be useful for CJD diagnosis. In sCJD almost all cases present gray matter 
hyperintensities in the neocortical, limbic and subcortical areas. In 70% to 90% of patients, 
cortical ribboning is evident that may be accompanied by increased intensities in the 
putamen and caudate nuclei detectable with fluid-attenuated inversion-recovery sequences 
and diffusion-weighted imaging (DWI) MRI (Geschwind et al., 2008). In vCJD, a 
characteristic MRI pulvinar sign is evident as hyperintensity in the pulvinar - posterior 
thalamus relative to the anterior putamen in about 80% of patients(Glatzel et al., 2005). In 
prolonged courses of sCJD (more than one year), brain MRIs show significant atrophy with 
loss of DWI hyperintensity, particularly in areas that previously displayed restricted 
diffusion (Vitali et al., 2011).  
In prion disorders associated with a high degree of amyloid deposition, such as GSS and other 
genetic variants, PET ligands that bind to prion-containing amyloid deposits, such as 2-(1-{6-
[(2-[F-18]fluoroethyl) (methyl)amino]-2-naphthyl}ethylidene)malononitrile (FDDNP), may 
offer additional diagnostic opportunities (http://www.medscape.com/viewarticle/582032_7). 
As with EEG results, these signs can also be found in other diseases, complicating the 
definitive diagnosis of a prion disease. 
5.4 14.3.3 detection 
The 14.3.3 proteins are a group of cytosolic polypeptides whose abnormal presence in the 
cerebrospinal fluid (CSF) can be detected in many conditions including stroke, infection, 
inflammatory processes, epileptic seizures, and toxic metabolic conditions, and is a reliable 
marker of the rapid destruction of neurons characteristic of a number of progressive 
neurological disorders (Zanusso et al., 2011).  
The use of 14.3.3 as a diagnosis for prion disease was suggested for the first time in 1996 (Hsich 
et al., 1996). Despite controversy regarding the specificity of this diagnostic tool, in 1999, 14.3.3 
detection was included by the WHO in their guidelines for CJD diagnosis. The 14.3.3 protein 
can be detected in many clinical laboratories; however, this is considered to be an expensive and 
time-consuming test that generates often inconclusive data due to the difficulty with which the 
protein band patterns can be discerned (Satoh et al., 2010). In spite of these limitations, 14.3.3 
tests are considered to be reliable diagnostic markers for CJD and present an approximately 
90% specificity and sensitivity in the diagnosis of sCJD. In addition, the presence of 14.3.3 in the 
CSF occurs in around 90% of fCJD cases. However, the presence of 14.3.3 has not been reported 
in the CSF of patients suffering from FFI or GSS (Glatzel et al., 2005).  
Other biochemical analyses of the CSF useful for CJD diagnosis are the presence of neuron-
specific enolase (NSE) and S100 proteins, which have been shown to be increased in the CSF 
of patients with CJD. The presence of Tau proteins in the CSF has also been described to be 
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diagnostic for CJD, but only in a small group of patients. Although the test for the presence 
of Tau is highly sensitive, it is not a differential diagnostic that can be used to distinguish 
CJD from other diseases (Otto et al., 2002).  
5.5 Neuropathological analysis 
The neuropathological hallmark of prion disease is the presence of the classical triad of 
spongiform changes, neuronal loss, and gliosis. As neuronal loss and gliosis are found in 
other neurodegenerative conditions, the spongiform changes in the brain are the most 
specific characteristic of prion disease. The spongiform changes may be mild, moderate, or 
severe, and are characterized by diffuse or clustered, small, round, or oval vacuoles in the 
neuropil (Budka, 2003) (Figure 4).  
 
Fig. 4. Spongiform degeneration: In sporadic CJD, some brain areas may have no 
(hippocampal end plate, at left), mild (subiculum, at middle) or severe (temporal cortex, at 
right) spongiform change. Haematoxylin and eosin (H & E) stain. Reproduced with 
permission from Budka, British Medical Bulletin 2003; 66: 121–130 (Budka, 2003). 
Other routine neuropathologic investigations include sampling from different regions of the 
CNS and the immunohistochemical detection of aggregated PrPSc. The type of PrPSc plaque 
deposition varies with the disease; synaptic-type deposits and unicentric PrPSc plaques 
occur in both CJD and GSS, while abundant multicentric plaques are peculiar to GSS. 
Plaque-like deposits are the only type of PrPSc deposits that extend to the subcortical white 
matter. Kuru plaques are present in a minority of sCJD cases and are most frequent in the 
cerebellar cortex (Budka, 2003) (Figure 5). GSS presents multicentric PrPSc plaques and 
thalamic degeneration, and also variable spongiform changes in cerebrum. 
 
Fig. 5. Patterns of PrPSc deposition: Cortical sections immunostained for PrPSc in sporadic 
CJD: synaptic (at left), patchy/perivacuolar (at middle) or plaque type (at right) patterns of 
PrPSc deposition. Reproduced with permission from Budka, British Medical Bulletin 2003; 
66: 121–130 (Budka, 2003). 
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In vCJD, a very particular pattern of PrPSc deposition is found. These depositions are 
composed of abundant multiple fibrillary PrPSc plaques surrounded by a halo of spongiform 
vacuoles called "florid" plaques or "daisy-like" plaques (Figure 6). Also present are 
amorphous pericellular and perivascular PrPSc deposits that are particularly prominent in 
the molecular layer of the cerebellum (Minor et al., 2004;Will et al., 1999;1997). 
 
Fig. 6. Amyloid plaques in prion diseases. Upper panel - Large Kuru-type plaque, Hematoxylin 
and Eosin stain. Lower panel - Typical ‘florid’ plaques in vCJD, H & E stain. Reproduced with 
permission from Budka, British Medical Bulletin 2003; 66: 121–130 (Budka, 2003). 
5.6 Tonsil biopsy 
The presence of PrPSc in postmortem tonsillar tissue was first described in a 35 year old 
woman in 1997. The immunohistochemical and western blot findings in this suspected vCJD 
case showed an abnormal PrPSc immunoreactivity within tonsillar germinal centers that are 
not observed in sCJD, suggesting that tonsil biopsy may be applicable as a differential 
diagnostic tool (Hill et al., 1997b). The WHO does not recommend tonsil biopsy routinely in 
cases in which EEG findings are typical of sCJD, but the biopsy may be useful in cases 
where the clinical features are compatible with vCJD and the MRI does not show a high 
bilateral pulvinar signal.  
5.7 Classification of sCJD and vCJD 
According to all the above clinical signs and symptoms, and the use of the before mentioned 
diagnostic exams, the WHO classifies sCJD and vCJD according to the following criteria: 
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Possible sCJD 
 Duration < two years 
 Progressive dementia 
 At least two of the following clinical features: myoclonus, visual or cerebellar 
disturbance, pyramidal, extrapyramidal dysfunction, akinetic mutism 
Probable sCJD 
 Duration < two years 
 Progressive dementia 
 At least two out of the following clinical features: myoclonus, visual or cerebellar 
disturbance, pyramidal, extrapyramidal dysfunction, akinetic mutism 
 The presence of 14.3.3 immunoreactivity in the CSF, or typical EEG patterns of periodic 
triphasic sharp waves 
Confirmed sCJD 
 Spongiform changes in cerebral and/or cerebellar cortex and/or subcortical grey matter 
 PrPSc immunoreactivity of the plaque and/or diffuse synaptic and/or patchy/ 
perivacuolar type  
Although the clinical criteria for CJD are fairly comprehensive, neuropathological analysis is 
important in every suspected case. The above criteria do not cover all CJD cases, and 
approximately 17% of all confirmed CJD cases do not fulfill clinical criteria for probable or 
possible CJD (Hainfellner et al., 1996;Radbauer et al., 1998).  
5.8 Variant CJD  
vCJD cannot be diagnosed with certainty using clinical criteria alone; the diagnosis requires 
neuropathological confirmation. The following combinations of signs, symptoms, and 
clinical investigations serve to define possible, probable, and definite vCJD (Table 4):  
 
(I)  
Progressive psychiatric disorder  
Clinical duration >6 months  
Routine investigations do not suggest an alternative diagnosis  
No history of potential iatrogenic exposure  
No evidence of a familial form of TSE (transmissible spongiform encephalopathies).  
 
(II)  
Early psychiatric symptoms (depression, anxiety, apathy, withdrawal, delusions)  
Persistent painful sensory symptoms (pain and/or dysaesthesia)  
Ataxia  
Chorea / dystonia or myoclonus  
Dementia.  
Possible vCJD 
 A patient with the items in (I) and at least four items in (II)  
 EEG is not typical of sCJD  
www.intechopen.com
 Transmissible Spongiform Encephalopathies 
 
205 
Probable vCJD 
 A patient with the items in (I) and at least four items in (II)  
 High bilateral pulvinar signal on MRI brain scan  
 EEG in not typical of sCJD, although generalized periodic complexes may occasionally 
be seen at the later stages of the disease. 
 Or, a patient with the items in (I) and a positive tonsil biopsy.  
Definite vCJD 
 A patient with the items in (I)  
 Neuropathological confirmation of vCJD 
 
HUMAN PRION DISEASE SPORADIC CJD VARIANT CJD 
Age at onset (range) 60-70y 26y (12-74) 
Disease Duration (range) 6 mo (1-35) 14 mo (6-24) 
Clinical Symptoms 
Progressive dementia, 
myoclonus, cerebellar ataxia, 
visual problems, 
extrapyramidal symptoms 
Early psychiatric symptoms, 
dysesthesia, later neurologic 
deficits and cognitive decline 
CSF 14.3.3 Positive > 90% Positive in 50% 
EEG PSWC 60-70% Nonspecific alterations 
MRI 
Brain atrophy hyperintensities 
in basal ganglia and/or 
cortical in 67% 
Hyperintensities in the 
posterior thalamus (pulvinar 
sign), 78% 
Histopathologic Features 
Spongiform changes, neuronal 
loss, astrogliosis, PrP 
deposition – various patterns 
Spongiform changes, neuronal 
loss, astrogliosis, PrP 
deposition – florid plaques 
Adapted from Glatzel et al, 2009. 
Table 4. Clinical, Diagnostic and Neuropathologic Features in Sporadic CJD and Variant CJD. 
Because of their potential infectious properties, the incidence of prion disease should be 
followed worldwide. The global surveillance of vCJD and other forms of CJD will lead to a 
better understanding of these diseases, including the potential causes of iCJD as well as the 
distribution of the various familial forms. Such epidemiology should also provide 
information useful for the protection of individuals against the risks of these diseases. The 
surveillance of CJD is recommended by the WHO and has been implemented in many 
countries including the UK, the US, Canada, Japan, Brazil, and many countries in Europe.  
6. Therapies and perspectives 
There are currently no effective means of curing or even ameliorating the symptoms of 
prion disease. There is currently a multitude of studies using different strategies aimed at 
finding effective treatments for these diseases (Rigter et al., 2010). The many attempts to 
achieve this goal are discussed in this section (Table 5).  
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Four types of studies have been conducted. These include the 1) in vitro observation of 
abnormal prions in a test tube, 2) the observation of cultured cells infected with prions, 3) 
studies involving prion-infected animals or 4) actual patients affected by the disease. No 
drug has shown efficacy in the treatment of animal models after the onset of symptoms, 
although several compounds have been shown to delay the onset of disease if given before 
symptoms are evident. 
The physiological functions of PrPC, as well as the exact molecular processes underlying its 
conversion into PrPSc, are not completely understood. Nevertheless, a number of 
compounds and techniques have been investigated for their therapeutic potential against 
prion disease. Current therapeutic strategies are focused upon preventing the accumulation 
of PrPSc in the nervous system. This can be accomplished by lowering PrPC availability, thus 
preventing PrPSc spread in the CNS, or by increasing PrPSc clearance. Additional non-
specific therapeutic strategies, such as stem cell therapy or the use of neurotrophic factors to 
prevent neuronal death, which have been tried in other protein conformational diseases 
such as AD, are emerging amongst prion researchers.  
The most direct strategy of inhibiting PrPSc conversion is to render PrPC unavailable. This 
may be accomplished by lowering the cellular amounts of PrPC. In mice, genetic deletion of 
PrPC confers resistance to prion diseases (Bueler et al., 1993). In humans, the ablation of PrPC 
may be possible via the recently-developed technology of interference RNA (RNAi). The 
transcription of DNA constructs that contain an antisense sequence to PrPC would produce 
an RNA molecule complementary to PrPC mRNA. This results in the annealing of both 
strands and the formation of a double-stranded RNA molecule, which activates a cellular 
mechanism of RNA degradation, thus preventing the translation and expression of PrPC. In 
cells, this technique was successful in inhibiting normal amounts of PrPC and its conversion 
to PrPSc (Daude et al., 2003). In mice inoculated with prions and allowed to incubate the 
disease until early neuropathology was established, a single injection of viral particles 
containing RNAi to PrPC prevented the onset of early behavioral and cognitive deficits, 
reduced PrPSc deposition and spongiosis, and resulted in the significantly increased survival 
of the animals (White and Mallucci, 2009). 
A potential drawback to the use of therapeutic RNAi in neurodegenerative diseases is the 
need to overcome the blood-brain-barrier (BBB); this would require either the transient 
disruption of the BBB’s impermeability or direct injection into the brain. However, in animal 
studies the efficacy of the viral delivery was restricted to the sites of injection. Therefore, 
protection against the formation of PrPSc in multiple areas of the brain would depend on 
several brain injections (White et al., 2008). Another caveat to the use of RNAi in vivo is the 
need to avoid silencing of unintended genes, cytotoxicity, activation of interferon responses, 
and interference with the processing of endogenous micro RNAs due to an over-loading of 
the RNAi pathway.  
In the treatment of prion disease, even a partial reduction of PrPC expression would likely 
be beneficial; thus low doses of RNAi should be sufficient, minimizing the potential for 
unintended side effects. An additional caveat of this strategy is that, since PrPC has many 
described functions, there may be undesirable side effects from its ablation. However, if a 
reversible process for gene silencing is developed, the physiological functions of PrPC could 
be restored following treatment. 
www.intechopen.com
 Transmissible Spongiform Encephalopathies 
 
207 
Therapeutic Strategy In vitro In vivo Human trials 
PrPc depletion by interference RNA Yes Yes n.d. 
Heterologous PrP Yes Yes n.d 
Amiloydogenic motif peptide Yes n.d. n.d. 
Dendritic Follicular Cell inhibition of 
differentiation 
Yes Yes n.d. 
Branched Polyamines Yes Yes n.d. 
β-breaker peptides Yes Yes n.d. 
Quinacrine Yes Limited efficacy Underway 
Active immunization n.d. Yes n.d. 
Passive immunization n.d. Yes n.d. 
Dextran Sulfate n.d. Yes n.d. 
Pentosan Polysulfate Yes Yes Not conclusive 
Heparin mimetic Yes Not conclusive n.d 
Congo red analogues Yes Yes n.d. 
Suramin analogues Yes Yes n.d. 
Poryphyrines/phtalocyanines Yes Yes n.d. 
Quinine/biquinoline Yes Some n.d. 
Tetracycline Yes Yes Underway 
n.d. – not determined. Adapted from: Vaccine 28 (2010) 7810–7823. 
Table 5. Overview of therapeutic strategies designed so far. 
A different strategy for reduction of PrPSc conversion is based upon the need for 
compatibility between the host PrPC and infectious PrPSc proteins for efficient conversion. 
Incompatibilities in PrPC between species, or from amino acid substitutions, may even block 
the conversion of compatible PrPC (Horiuchi et al., 2000). For example, treatment of prion-
infected mice with viral particles expressing PrPC containing specific mutations increased 
survival time, even when treatment was started at a late stage of infection (Toupet et al., 
2008). In this manner, the expression of incompatible PrPC may be a viable therapeutic 
strategy in prion disease, without the drawback of impairing normal PrPC functions. This 
approach has been applied to sheep in the Netherlands, where the preferential breeding of 
resistant phenotypes has been widely and effectively implemented. The difficulties of this 
treatment rely on the need of a continuous means of delivery for the resistant PrPC forms 
that would also efficiently spread this molecule throughout the brain.  
In addition to conversion-resistant PrPC proteins, the introduction of peptides from a 
conserved region of PrPC are also able to block conversion (Chabry et al., 1999). Even though 
peptides are easily synthesized, they have the disadvantage of being sensitive to proteolytic 
degradation and, like the PrPC protein, the difficulties in crossing the BBB requires 
intracranial injections.  
Alternatively, the prevention of PrPSc migration to the CNS can block the progression of the 
disease without the need of bypassing the BBB. In cases where infection is acquired, PrPSc 
must spread to the nervous system. Studies suggest that PrPSc first accumulates on follicular 
dendritic cells, from where neuronal invasion occurs. The experimental impairment of 
dendritic cell maturation was shown to inhibit prion neuroinvasion. However, this 
approach was most successful when treatment was administered prior to scrapie 
inoculation (Mabbott et al., 2003;Montrasio et al., 2000), and would not be effective against 
the familial prion diseases. 
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The study of the mechanisms by which PrPSc induces neurodegeneration also promises new 
therapeutic strategies. For example, the calcium-dependent phosphatase calcineurin (CaN) 
was shown to be hyperactivated as a result of PrPSc formation. Prion-infected mice treated 
with the CaN inhibitor FK506 at the clinical phase of the disease exhibited reduced severity 
of the clinical abnormalities and increased survival times. These animals also displayed a 
reduced degree of neurodegeneration that was independent of the amount of PrPSc, 
suggesting that inhibition of PrPSc formation may not be necessary for therapeutic effects 
with FK506 (Mukherjee et al., 2010). 
At the current time, no protein conformational disorder has a highly effective therapy. Many 
studies using AD animal models have shown that immunotherapeutic approaches can 
reduce both amyloid and tau-related pathology, leading to cognitive rescue. Partly because 
of success observed in AD models, similar experiments with anti-PrP antibodies were 
initiated. In tissue culture studies, anti-PrP antibodies and antigen-binding fragments 
directed against PrP have been shown to inhibit prion replication. Administering specific 
anti-PrP monoclonal antibodies directly following the inoculation of mice with prions, 
resulted in prolonged survival in treated animals (Sigurdsson et al., 2003) and continuous 
treatment with antibodies delayed the incubation period (White et al., 2003). Passive 
immunization of extra-cerebrally infected mice with an anti-PrP antibody resulted in the 
effective suppression of PrPSc replication in the linforeticular system, effectively preventing 
prion invasion into the CNS (Sadowski et al., 2009). In a different approach, the artificial 
expression of the anti-PrP antibody 6H4 protected mice from prion disease following prion 
inoculation (Heppner et al., 2001).  
Potential complications of this immunotherapy approach can arise from the fact that in vivo 
cross-linking with PrPC-specific antibodies has been shown to trigger rapid and extensive 
apoptosis in neurons (Solforosi et al., 2004). Additionally, passive immunization has not 
been found to be effective when administered close to the clinically symptomatic stages of 
prion infection. Additionally, this approach would be too costly for the treatment of prion 
diseases in animals. 
Active immunization (vaccination) was also shown to prolong the survival of infected mice, 
especially when vaccination occurred prior to prion exposure (Sigurdsson et al., 2002; 
Schwarz et al., 2003). Full-length PrPC, or a peptide sequence of PrPC, were expressed in 
mice using viral particles resulting in the production of high-affinity antibodies able to 
inhibit PrPSc formation in prion-infected cells (Nikles et al., 2005;Handisurya et al., 2007). 
Trials using this methodology to prevent Chronic Wasting Disease in mule deer are 
ongoing.  
A drawback of active immunization is that endogenous PrPC functionality would be 
indefinitely impaired in the treated animal. Additionally, immunomodulation to target 
prions must overcome the body’s natural tolerance to endogenous PrPC at the same time 
that humoral or cellular autoimmune cytotoxic effects should be avoided or minimized 
(Wisniewski and Goni, 2010). 
Preventing the accumulation of PrPSc is also a viable therapeutic strategy, and a number of 
compounds have been examine for this purpose. Branched polyamines were shown to 
disaggregate prion aggregates, rendering PrPSc susceptible to proteolysis. Although the 
mechanisms are not clear, these compounds appear to interact with PrPSc, resulting in the 
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blockade of de novo PrPSc formation and increased PrPSc clearance. However, the in vitro 
susceptibility of PrPSc to polyamine treatment was strain-dependent, limiting its application 
(Supattapone et al., 2001;Solassol et al., 2004). Peptides that disrupt protein -sheets also can 
increase the susceptibility of PrPSc to protease degradation. A peptide capable of disrupting 
-sheet structure was shown to reverse the inherent protease resistance of PrPSc, preventing 
prion formation in infected cultured cells and increasing the survival of mice inoculated 
with PrPSc (Soto et al., 2000). In this case, the same drawbacks described for other peptide 
treatments, namely BBB penetrability and protease susceptibility, still apply. 
A number of other classes of compounds have also been tested for the ability to inhibit PrPSc 
accumulation. Polyanionic glycans, such as sulphated glycans, are known to non-specifically 
and indirectly inhibit the entry of viruses in cells and were first tested when prions were 
thought to be an unconventional virus. Pentosan polysulfate (PPS) showed promise as a 
therapeutic when administered directly into the cerebral ventricular system of a vCJD 
patient (Todd et al., 2005); however, these results were not replicated in other patients 
(Whittle et al., 2006). A recent monitoring study of seven British patients treated with PPS 
showed that, in spite of complications related to the administration itself, some of the 
patients treated with PPS appear to have survived for long periods (Bone et al., 2008) 
(http://www.prion.ucl.ac.uk/clinic-services/research/drug-treatments). It cannot be 
concluded, however, that the PPS treatment itself had a beneficial effect, as it was impossible 
to make direct comparisons with similar, but untreated, patients. It is also very difficult to 
determine exactly the time of disease onset, and this obviously affects the estimation of 
survival time. An drawback of polyanions is that their penetration of the BBB is minimal, 
again requiring direct brain administration. 
Heparan mimetics (Congo Red, porphyrins and phtalocyanins) are among the first 
compounds identified as capable of binding to PrPC and preventing PrPSc production 
(Caughey and Race, 1992). Congo Red displayed an ability to inhibit PrPSc, but is also 
limited in its ability to pass the BBB. Additionally, Congo Red can be cleaved in the 
mammalian gut and intestines to release highly carcinogenic benzidine. Curcumin shares 
many properties of Congo Red without its toxicity, and was demonstrated to share its 
properties as an effective inhibitor of PrPSc formation (Caughey et al., 2003). Curcumin 
treatment in mice was shown to result in a significantly prolonged survival time (Riemer et 
al., 2008).  
Porphyrins and phtalocyanines are classes of compounds that were shown to 
prophylactically inhibit PrPSc formation and prolong survival in hamsters. Nevertheless, 
treatment at the onset of clinical symptoms did not result in significantly prolonged survival 
rates (Priola et al., 2000). Recently, poly-L-lysine polymers were also shown to strongly 
inhibit PrPSc propagation in vitro, in cell culture, and in mouse models of prion disease 
(Ryou et al., 2011).  
Acridine and phenothiazine derivatives, which include the antimalarial and antipsychotic 
drug quinacrine, can pass the BBB and are effective inhibitors of PrPSc formation both in 
vitro and in cultured cells (Barret et al., 2003;Doh-ura et al., 2004). Even though quinacrine 
did not show anti-prion effects in infected rodents, this drug has been used extensively as an 
experimental treatment in CJD patients (Nakajima et al., 2004;Martinez-Lage et al., 2005). 
Although treatment sometimes resulted in slight improvement in patients’ condition, this 
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improvement was temporary and quinacrine treatment did not significantly delay disease 
progression. Following reports of improvement after quinacrine administration, two clinical 
trials were initiated. PRION-1 was led by Drs. Collinge and Darbyshire at the National Prion 
Clinic in the UK (http://www.prion.ucl.ac.uk/clinic-services/research/drug-treatments). 
The headline-making results of PRION-1 were published in 2009 and unfortunately  
showed no survival benefit of quinacrine (Collinge et al., 2009). A separate trial based  
in San Francisco, US, is currently active, led by Dr. Michael Geshwind 
(http://clinicaltrials.gov/ct2/show/NCT00183092?term=prion&rank=2). In addition, 
newer compounds with structures similar to quinacrine, trimipramine, and fluphenazine, 
have been shown to prolong the asymptomatic incubation period of prion infection, as well 
as to significantly reduce the degree of spongiosis, astrocytosis, and PrPSc levels in the brains 
of treated mice (Chung et al., 2011).  
Tetracyclines also have been tested in prion therapy. Tetracycline efficiently crosses the BBB 
and can interact with amyloid fibrils that mimic the central features of the proteinase-
resistant core of PrPSc. Incubation of tetracycline with purified PrPSc results in diminished 
proteinase resistance. Doxycycline administration leads to prolonged survival when 
administered 30 days after prion inoculation in mice. Preliminary data from observational 
studies in humans, in which doxycycline is administered for compassionate reasons, show 
to significantly prolong the survival of CJD patients, confirming the anti-prion activity of 
tetracyclines in humans. A drug vs. placebo clinical study is currently underway (Rigter et 
al., 2010) (http://www.prion.ucl.ac.uk/clinic-services/research/drug-treatments).  
Interestingly, compounds that block amyloid aggregation may reach the clinic for the 
treatment of systemic amyloidoses long before amyloid-targeted drugs for 
neurodegenerative disorders, as these systemic disorders do not require compounds that 
cross the BBB. For example, transthyretin amyloidosis (ATTR) is caused by the deposition of 
transthyretin (TTR) amyloid fibrils in various tissues. The hereditary form of ATTR is 
caused by amyloidogenic mutations leading to abnormally folded monomers that self-
assemble to amyloid fibrils. These TTR amyloid fibrils are then deposited extracellularly in 
various tissues. Two such compounds for the treatment of ATTR amyloidosis (Tafamidis 
from Pfizer and Scyllo-inositol from Elan) are currently in Phase III clinical trials (Aguzzi 
and O'Connor, 2010).  
Alternative to the strategies aimed at reducing PrPSc accumulation, temptative therapies 
involving regeneration of the damaged tissues are also in progress. Cell therapy, which has 
been in trials for other neurodegenerative disorders, such as AD, is beginning to emerge as a 
viable option for prion diseases. In prion disease, intracerebral transplantation of fetal 
neural stem cells significantly extended both the incubation and survival time in mice, 
suggesting that stem cell therapy may be an effective possibility for human prion diseases 
(Relano-Gines et al., 2011). 
The above mentioned therapeutic strategies all focus on impairing neurodegeneration 
engendered by these conditions. Nonetheless, for some neurodegenerative diseases, it has 
been proposed that compromised synaptic function is one of the earliest symptoms. 
Synaptic connectivity between neurons is critical for their survival and thus loss of 
synapses, spines, and dendrites precedes the loss of neuronal cell bodies. On the other hand, 
while synapses have an intrinsic plasticity and can be potentially replaced, neuronal loss is 
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thus far irreversible. This knowledge means that the early stages of disease represent a 
highly attractive target for treatment. In prion diseases, it was recently demonstrated that 
mice experimentally infected with prions show changes in motivational behaviors long 
before the emergence of motor signs, and that these behavioral changes correlate with 
synaptic loss. Further, preventing neuronal death, but not synaptic dysfunction, does not 
halt the development of clinical disease in mice (Moreno et al., 2003; White and Mallucci, 
2009; Verity and Mallucci, 2011). Many of the proposed therapies, therefore, may prove 
effective if administered at the time of synapse loss, rather than at the later stage of neuronal 
death. Thus, the identification of early dysfunction would help to direct therapies towards 
the earlier stages of disease, when rescue may still be possible. This may reflect a critical 
window for neuronal rescue that depends upon the kinetics of prion spread. The pre-clinical 
diagnosis of TSE is therefore of importance in the improvement and development of new 
therapies. 
Ideally, a successful prion disease therapy should be able to cross the BBB or be delivered to 
the CNS, be non-toxic and effective at physiological concentrations, be efficient even after 
PrPSc accumulation, and would either not compromise PrPC functionality or would allow for 
its restoration. Unfortunately, current therapeutic strategies are either only useful as a 
prophylactic or their applicability in vivo remains to be determined.  
There are currently only a small number of clinical trials for treatment of CJD patients. Most 
reports include a single patient, and very few studies have been conducted under strict 
conditions. Due to the rarity of these diseases, studies usually contain a mixture of patients 
with different prion diseases with the assumption than the treatment may be effective for all 
of them. This is not necessarily true, as different prion strains may exhibit different 
sensitivities to drug treatments. 
In the future, a combination of therapies aimed lowering the amount of PrPC available for 
conversion with other strategies may prove the most effective. For example, the combination 
of RNAi against the PrPC  mRNA with a drug to increase endogenous clearance of PrPSc may 
be likely to delay disease progression. Hence, potential therapies need not aim for the total 
ablation of aberrant protein expression, but instead could have the lowering levels of 
expression below the cellular threshold for clearance as their goal. Of course, from a public 
health perspective, the elimination of neurotoxicity without abolishing prion replication 
maintains infectivity, leaving open the possibility of prion transmission. 
While the ablation of PrPC expression in adult mice is well tolerated, the consequences of 
reducing PrPC in humans remain unknown. It may be that the risk-benefit ratio of the 
possible adverse effects of PrPC loss against the potential for improved survival and 
protection against neuronal loss will determine future therapies for prion and other neu-
rodegenerative disorders.  
7. Concluding remarks  
Prion diseases have represented a challenge to researchers and clinicians since the discovery 
of scrapie and kuru. The determination that scrapie, kuru, and CJD are related diseases and 
that they are both hereditary and transmissible, was a task that took many decades to 
resolve. 
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The discovery of the nature of the etiological agent responsible for these diseases also 
represented a breakthrough in the traditional concepts of molecular biology, and modified the 
paradigm that stated that flow of genetic information was mediated only by nucleic acids. A 
small number of proteins, particularly in yeast, are now known to have prion properties and 
are able to transmit information to their offspring (Uptain and Lindquist, 2002). Even more 
impressive, other neurodegenerative diseases, such as taupathies, have recently been 
demonstrated to be transmissible in transgenic mouse models (Clavaguera et al., 2009).  
Although much progress has been made in the understanding of prion disease, many 
unanswered questions remain. For example, the exact molecular mechanism by which the 
PrPC alteration leads to neurodegeneration is unknown. As a consequence, no effective 
therapy against these diseases has been developed. Also lacking is a precise, low-cost, high-
throughput diagnostic tool, and an advance in this aspect could contribute to the chances of 
a successful therapy, due to the possibility of detecting the illness before the onset of clinical 
symptoms.  
The realization that diseases characterized by protein conformational disorders have many 
aspects in common is also a recent development. The presence of soluble oligomeric forms 
of the proteins responsible for these different diseases is currently recognized as the most 
likely entities to induce neuronal damage, and plaques and proteinaceous aggregates are 
now though to play potentially protective roles in sequestering toxic oligomeric proteins. 
Thus, successful diagnostic or therapeutic strategies directed at one of these diseases will 
likely open new fields for all the others.  
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